BofA cuts Lazard stock price target on weak advisory revenue By Investing.com

BofA cut Lazard’s price target to $60 from $63 while keeping a Buy rating after Q1 EPS of $0.42 missed estimates of $0.55 and consensus of $0.51. Revenue weakness in Financial Advisory and weaker-than-expected AUM, down 6.5% vs BofA’s forecast, offset only partly by a lower tax rate; the stock has already fallen 8.4% over the past week to $45.13. Morgan Stanley also lowered its target to $53 from $52 and cut 2026 EPS estimates by $0.47 to $2.76.

Analysis

The key issue is not the quarter itself but the direction of travel in AUM and advisory fee momentum. For a capital-light franchise like LAZ, small changes in deal activity and market levels can cause disproportionate swings in forward EPS, so the market is likely discounting a slower recovery in M&A rather than one soft print. The recent analyst revisions also matter because they can mechanically compress the valuation multiple even if earnings only drift lower, which helps explain why the stock can underperform despite a still-respectable dividend.

Second-order, the weaker advisory line signals pressure on the broader boutique M&A complex, especially names that rely on sponsor-driven and mid-market deal flow. If markets stay choppy and equity issuance remains muted, asset-management stability will not be enough to offset advisory leverage, and relative winners should be platforms with more recurring revenue or stronger balance-sheet advisory capabilities. That argues for a selective stance within financials rather than treating this as a broad sector signal.

The contrarian case is that expectations may now be low enough that modest stabilization in equity markets or a few larger mandates can drive a sharp rebound, since the stock has already de-rated and still screens as income-supported. The risk is timing: this is a months-long recovery story, not a days-long trade, because fee pools lag market turns and corporate confidence typically needs sustained calm before transaction activity improves. Near-term, any further cuts to forward estimates are the main catalyst for another leg down; conversely, a cleaner read on pipeline or improved market breadth could trigger a squeeze in a name that has already absorbed a lot of bad news.

Key Decisions for Investors

• Short LAZ on rallies over the next 2-6 weeks if the stock reclaims pre-earnings levels; use a stop above the latest analyst target band, since a deal-market inflection could produce a sharp mean reversion.
• Pair trade: long a higher-quality diversified asset manager or bank advisory platform vs. short LAZ for 1-3 months, betting that recurring revenue and broader balance-sheet leverage outperform pure advisory beta if M&A stays weak.
• Buy LAZ put spreads 1-2 quarters out rather than outright shorting stock if you want defined risk; the setup favors downside follow-through from estimate cuts, but dividend support can slow the tape.
• For long-only accounts, wait for evidence of AUM stabilization and management commentary on pipeline before adding; the best entry is likely after another estimate reset, not on the first bounce.